Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 3/20 | 0.61 |
| ▸ | HTR1A | P08908 | 3/20 | 0.61 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.61 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.61 |
| ▸ | DRD2 | P14416 | 2/20 | 0.55 |
| ▸ | DRD3 | P35462 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | HTR1D | P28221 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7776926 | 0.89 | ADRA1A (0.67) | ADRA1AHTR1AADRA1DADRA1BDRD2 | |
| SCHEMBL7781578 | 0.85 | DRD2 (0.62) | ADRA1AHTR1AADRA1DADRA1BDRD2 | |
| SCHEMBL4473040 | 0.84 | KDM4E (0.54) | ADRA1AHTR1AADRA1DADRA1BDRD2 | |
| SCHEMBL7801405 | 0.83 | DRD2 (0.55) | ADRA1AHTR1AADRA1DADRA1BDRD2 | |
| SCHEMBL13698446 | 0.82 | DRD2 (0.61) | ADRA1AHTR1AADRA1DADRA1BDRD2 | |
| SCHEMBL13919809 | 0.79 | DRD2 (0.57) | ADRA1AHTR1AADRA1DADRA1BDRD2 | |
| SCHEMBL4490404 | 0.78 | DRD2 (0.58) | ADRA1AHTR1AADRA1DADRA1BDRD2 | |
| SCHEMBL13919815 | 0.78 | DRD2 (0.60) | ADRA1AHTR1AADRA1DADRA1BDRD2 | |
| SCHEMBL13373129 | 0.77 | ACKR3 (0.58) | ADRA1AHTR1AADRA1DADRA1BKDM4E | |
| SCHEMBL13372998 | 0.77 | ACKR3 (0.58) | ADRA1AHTR1AADRA1DADRA1BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140838-A1 | 1, 4-PIPERAZINE DERIVATIVES HAVING 5HT1A RECEPTOR ACTIVITY | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-10-10 | — | — | EP | claimed |
| US-20010014680-A1 | 1,4-piperazine derivatives | WYETH | 2001-08-16 | — | — | US | claimed |
| US-6255302-B1 | NERVOUS SYSTEM, PSYCHOLOGICAL DISORDERS | AMERICAN HOME PRODUCTS CORPORATION | 2001-07-03 | — | — | US | claimed |
| WO-2000035878-A1 | 1,4-PIPERAZINE DERIVATIVES HAVING 5HT1A RECEPTOR ACTIVITY | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-22 | — | — | WO | claimed |
| US-20010014680-A1 | 1,4-piperazine derivatives | WYETH | 2001-08-16 | — | — | US | disclosed |
| US-6255302-B1 | NERVOUS SYSTEM, PSYCHOLOGICAL DISORDERS | AMERICAN HOME PRODUCTS CORPORATION | 2001-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010014680-A1 | 1,4-piperazine derivatives | ADH1A, ADH1C, SNCA | ADRA1A 38/4885HTR1A 8/4885ADRA1D 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.